Strange Bedfellows: Generics Firms Join Big Pharma In Opposing Price Negotiation Legislation

 
• By Cathy Kelly

Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.

Innovator And Generics/Biosimilars Sectors Often Not On Same Side • Source: Alamy

More from Pricing Debate

More from Market Access